LAMP1 and Alzheimer disease: Furthermore, the reduction in LAMP1‐positive dystrophic neurites associated with Aβ plaques indicates that Enavogliflozin treatment mitigates plaque‐induced neuronal damage, a critical aspect of AD pathology.